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Background: We evaluated the association between a KRAS mutational status and various clinicopathologic
features including the metastatic pattern in patients with metastatic or recurrent colorectal cancer (MRCRC).
The concordance rates of the KRAS status between primary tumor sites and paired metastatic organs
were also analyzed.
Methods: The KRAS mutational status in codons 12, 13, and 61 from formalin-fixed sections of both primary tumors
and related metastases was determined by sequencing analysis. One hundred forty-three Korean patients with
MRCRC with available tissues (resection or biopsy) from both primary tumors and related metastatic sites were
consecutively enrolled.
Results: The KRAS mutation rate was 52.4% (75/143) when considering both the primary and metastatic sites.
When the relationship between the KRAS status and initial metastatic sites at the time of diagnosis of MRCRC was
analyzed, lung metastasis was more frequent as the initial metastatic site in patients with the KRAS mutation than
in patients without the KRAS mutation (45.3% vs. 22.1%; P = 0.003). However, liver (37.3% vs. 70.6%; P < 0.001) or
distant lymph node metastases (6.7% vs. 19.1%; P = 0.025) were less frequent as the initial metastatic organ in
patients with the KRAS mutation than in patients without the KRAS mutation. The discordance rate of KRAS
mutational status between primary and paired metastatic sites other than the lung was 12.3% (13/106). Compared
with primary tumor sites, the KRAS discordance rate was significantly higher in matched lung metastases [32.4%
(12/37)] than in other matched metastatic organs (P = 0.005).
Conclusions: Organs initially involved by distant metastasis were different according to the KRAS mutational status
in MRCRC patients. The concordance rate (87.7%) of the KRAS mutation status at metastatic sites other than the
lung was generally high compared with primary tumor sites; however, lung metastasis had a high rate of KRAS
discordance (32.4%).
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Colorectal cancer (CRC) is the most common gastrointes-
tinal cancer, and one of the leading causes of cancer deaths
worldwide [1]. Recently, the incidences of CRC have been
increasing in Asian countries including Korea [2]. Meta-
static or recurrent colorectal cancer (MRCRC) has a poor
prognosis. Many recent studies have demonstrated that
MRCRC with KRAS mutant-type (MT) are resistant to
anti-epidermal growth factor receptor (EGFR) agents such
as cetuximab or panitumumab, which showed efficacy as
monotherapy or in combination with cytotoxic agents in
MRCRC patients with a wild-type (WT) genotype in
KRAS codons 12 and 13 [3-6]. KRAS mutational analysis
of primary or metastatic tumor tissues is recommended for
all MRCRC patients receiving anti-EGFR chemotherapy.
The KRAS mutation is known to occur in about 40% of
all CRC cases [7]. The activating mutation of KRAS
induces stimulation of the RAS/MAPK signaling pathway
independent of EGFR, subsequently followed by dysregu-
lated cell growth, proliferation, and survival [8]. However,
the actual differences in clinical behaviors between tumors
with WT and MT KRAS, except resistance to anti-EGFR
agents, remain controversial. There have been some
reports showing that MT KRAS tumors have a poorer
prognosis than WT KRAS tumors; however, such a rela-
tion between KRAS status and prognosis in CRC was not
verified in other reports [9-13]. Recently, it has been
reported that the recurrence pattern after the curative re-
section of CRC is determined according to the KRAS mu-
tational status, showing the positive correlation of KRAS
mutation with lung relapse [14,15]. Furthermore, some
reports demonstrated a different prognosis and clinical
presentation with respect to the mutation types of the
KRAS gene [16,17]. However, these findings need to be
confirmed by additional studies.
In addition, WT KRAS tumors are not always sensitive to
EGFR-targeted therapy. Many studies have focused on the
downstream signaling pathways of EGFR with the goal of
identifying other predictive factors for patients resistant to
anti-EGFR agents. BRAF or PIK3CA mutation and PTEN
loss were suggested as other biomarkers predicting a lack
of response to anti-EGFR agents [18-21]. Since the BRAF
mutation or PTEN loss are rare [22], other mechanisms of
resistance to anti-EGFR agents are expected to play a sub-
stantial role. Although the KRAS mutation is believed to
be an early event in the carcinogenesis of CRC [23] and it
has been demonstrated that the KRAS mutational status is
highly concordant between primary tumors and related
metastases [14,15,24-28], some recent studies have pro-
duced contradictory results in regards to the KRAS muta-
tional status [11,29-31]. Especially, most previous studies
on the concordance of the KRAS mutation status were
conducted on easily available hepatic metastatic tissues [24,
26,28]. Therefore, if the discordant rate is differentaccording to the respective metastatic organs, it may also
contribute to a poor response to anti-EGFR agents.
Therefore, this study was performed to determine
whether there are differences in clinical behavior such as
metastatic patterns according to the KRAS mutational sta-
tus in MRCRC patients. Additionally, the concordance
rates of KRAS mutation status between primary sites and
respective metastatic organs were also evaluated.
Methods
Study population
Among patients with histologically confirmed colorectal
adenocarcinoma who had been treated or followed up at
medical oncology clinics of Seoul National University Bun-
dang Hospital (SNUBH) between April 2010 and February
2011, 151 MRCRC patients who had undergone surgical re-
section or biopsy of both primary tumors and related meta-
static sites were consecutively enrolled. Eight patients were
excluded because of a failure in the process of KRAS muta-
tional analysis on either primary or metastatic site, thus 143
patients were finally included in this study. The clinical data
on enrolled patients was retrieved from the CRC database
maintained at SNUBH [32], and additional data collection
was retrospectively supplemented after a review of the elec-
tronic medical record (EMR). This study was approved by
the institutional review board of SNUBH.
Preparation of tumor DNA and sequence analysis of
KRAS gene
Formalin-fixed paraffin-embedded primary tumor and meta-
static tissue specimens were chosen for each patient and all
specimens were microdissected manually under the supervi-
sion of experienced gastrointestinal pathologists. After man-
ual microdissection, > 60% of the sample area was shown to
contain tumor cells as estimated from the H&E-stained
slides. The DNA was extracted using a chelating ion ex-
change resin (InstaGene Matrix, Bio-Rad). For mutation ana-
lyses in codons 12, 13, and 61 of the KRAS gene, extracted
tumor DNA samples were subjected to automated sequen-
cing using an ABI 3130xl Genetic Analyzer (Applied Biosys-
tems) and the data was analyzed with GeneMapper Software
Version 4.0 (Applied Biosystems). Primer sequences for exon
1 were 5’-AACCTTATGTGTGACATGTTCTA-3’ (forward)
and 5’-TGGTCCTGCACCAGTAAT-3’ (reverse); for exon 2,
5’-ACTGTAATAATCCAGACTGTGTT-3’ (forward) and
5’-CCCACCTATAATGGTGAATATCT-3’ (reverse). The
polymerase chain reaction (PCR) conditions were as follows:
one cycle of 95°C for 5 minutes; 34 cycles of 95°C for 30 sec-
onds, 58°C for 30 seconds, and 72°C for 1 minute; and one
cycle of 72°C for 10 minutes.
Determination of microsatellite instability (MSI) status
The MSI status of paired normal and tumor DNA samples
was assessed using the Bethesda panel of 5 microsatellite
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system as the KRAS mutational analysis. The MSI status
was classified as high frequency if ≥ 2 of 5 markers exhib-
ited instability, as low frequency if one marker exhibited
instability, and as stable if no markers exhibited instability.
Statistical analysis
The concordance rate of KRAS mutational status in pri-
mary tumors and related metastases was evaluated; the
Kappa index was measured using Cohen’s k-test, which
can assess the concordance between categorical variables
of the same individuals. The effect of KRAS mutational sta-
tus on clinicopathologic parameters and initial metastatic
sites were assessed using Pearson’s chi square or Fisher’s
exact tests. Multivariate logistic regression analyses were
performed to evaluate the effect of other clinicopathologic
features on liver-only and lung-only metastases besides the
KRAS status. The relationship between the discordant
rates of the KRAS mutation status and various clinical
parameters including respective metastatic sites was also
evaluated using univariate (Pearson’s chi square or Fisher’s
exact tests) and multivariate logistic regression analyses. In
multivariate logistic regression analysis, the forward stepwise
regression model including variables with a P-value < 0.10
in univariate analysis was used. Two-sided P-values of
< 0.05 were considered significant. All analyses were per-




Of the 143 patients included in this study, 77 patients
(53.8%) were male. The median age was 59 years (range,
20–83 years). Paired metastatic sites for KRAS analysis
were liver (N = 47), lung (N = 37), peritoneum (N = 30),
distant lymph nodes (LN) (N = 17), ovary (N = 11) and
pancreas (N = 1), respectively. Most patients had stage IV
disease (distant metastasis) at the time of initial CRC diag-
nosis (N = 101, 70.6%), and only 42 patients had recurred
disease after curative resection for localized disease (stage I
to III at the time of initial CRC diagnosis). The primary
tumor sites were colon in 108 patients (76.5%) and rectum
in 35 (23.5%). Other patient characteristics are shown in
Table 1.
Frequency and types of KRAS mutation
The KRAS mutation was observed in 62 (43.4%) primary
tumors and at 63 (44.1%) related metastatic sites. Seventy-
five patients (52.4%) had the KRAS mutation in any place
of the primary or metastatic sites. Of those 75 patients, 20
patients had a Gly12Asp mutation, 18 had a Gly13Asp mu-
tation, 17 had a Gly12Val mutation, 9 had a Gly12Cys, 3
had a Gly12Ala, and other 3 patients had a Gly12Ser. In
addition, 2 patients had a Gln61Leu mutation andGly13Cys (N =1), Gln61His (N = 1), and Gln61Arg muta-
tion (N = 1) were detected in the remaining 3 patients
(Table 2). The incidence of codon 61 mutations was 5.3%
among patients with the KRAS mutation (4 of 75 cases).
Concordance of KRAS status in primary tumors and
related metastases
KRAS status was concordant between primary and meta-
static sites in 118 patients (82.5%; kappa = 0.645) (Table 3).
Of the 25 discordant cases, 12 patients had the KRAS mu-
tation in the primary tumors, and not in the metastatic
sites; 13 patients had the KRAS mutation in the metastatic
tumors, and not in the primary tumors. We analyzed the
difference in discordance pattern according to clinical
presentation (stage IV vs. recurred) at the time of initial
MRCRC diagnosis and metastatic organs from which tis-
sue specimens were obtained. There were no statistically
significant differences in discordance patterns with respect
to these parameters (Table 4).
Association between KRAS mutational status and
clinicopathologic features
Clinical situations for the development of systemic metas-
tasis in MRCRC patients were different according to the
KRAS mutational status. In regards to the development of
distant metastasis, systemic relapse from previously loca-
lized CRC (stages I to III) after complete surgical resection
was more frequent in MT KRAS patients than in WT
KRAS patients (38.7% vs. 19.1%); however, systemic me-
tastasis was more frequent at the time of initial CRC diag-
nosis in WT KRAS patients than in MT KRAS patients
(80.9% vs. 61.3%; P = 0.010).
There was no association between the KRAS status and
other clinicopathologic features (gender, age, primary tumor
location, histology, gross morphology, obstruction or perfor-
ation of primary tumors, and MSI) (Table 1).
KRAS mutational status and metastatic patterns
When the relationship between KRAS status and initial
metastatic sites at the time of diagnosis of stage IV disease
or recurrence (in the cases of initial stages I to III) was
analyzed (N = 143), patients with MT KRAS had a higher
rate of initial lung metastasis (45.3%) than patients with
WT KRAS (22.1%; P = 0.003). However, a higher percent-
age of liver or distant LN metastases was detected in
patients with WT KRAS when compared to patients with
MT KRAS (70.6% vs. 37.3%, P < 0.001 for liver; 19.1% vs.
6.7%, P = 0.025 for LN). Peritoneal or ovarian metastases
showed no significant difference according to the KRAS
mutational status (P-values > 0.05) (Table 5). Regarding
other initial metastatic sites including bone (N = 3), kidney
(N = 2) and so on, comparison could not be made due to
too few cases.
Table 1 Patient characteristics (N = 143) and the association between KRAS mutational status and clinicopathologic
parameters
Characteristic No. of patients
All KRAS WT KRAS MT P-value
N N (%) N (%)
Gender 0.897
Male 77 37 (54.4) 40 (53.3)
Female 66 31 (45.6) 35 (46.7)
Age 0.303
< 65 years 97 49 (72.1) 48 (64.0)
≥ 65 years 46 19 (27.9) 27 (36.0)
Clinical situations for the development of systemic metastasis 0.010
Stage IV at the time of initial diagnosis 101 55 (80.9) 46 (61.3)
Recurred after curative resection 42 13 (19.1) 29 (38.7)
Primary site 0.802
Colon 108 52 (76.5) 56 (74.7)
Rectum 35 16 (23.5) 19 (25.3)
Histology and grade 0.819
ADC, well differentiated 5 2 (2.9) 3 (4.0)
ADC, moderately differentiated 118 56 (82.4) 62 (82.7)
ADC, poorly differentiated 12 7 (10.3) 5 (6.7)
ADC, mucinous 8 3 (4.4) 5 (6.7)
Gross morphology of primary tumor 0.421
Ulceroinfiltrative 66 33 (48.5) 33 (44.0)
Ulcerofungating 63 28 (41.2) 35 (46.7)
Polypoid 7 2 (2.9) 5 (6.7)
Unknown 7 5 (7.4) 2 (2.7)
Obstruction of primary tumor 0.371
Yes 43 18 (26.5) 25 (33.3)
No 100 50 (73.5) 50 (66.7)
Perforation of primary tumor 1.000
Yes 10 5 (7.4) 5 (6.7)
No 133 63 (92.6) 70 (93.3)
Microsatellite instability 0.343
Stable 121 58 (85.3) 63 (84.0)
Low frequency 11 3 (4.4) 8 (10.7)
High frequency 2 1 (1.5) 1 (1.3)
Unknown 9 6 (8.8) 3 (4.0)
Abbreviations: WT, wild-type; MT, mutant-type; ADC, adenocarcinoma.
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metastasis confined to a single organ at the time of diag-
nosis of stage IV or recurred disease was also analyzed
(N = 113). A higher rate of lung-only metastasis was
observed in MT KRAS cases (41.0%) compared with
WT KRAS cases (11.5%; P < 0.001). Liver-only metasta-
sis was more frequently observed in WT KRAS cases
(65.4%) than in MT KRAS cases (27.9%; P < 0.001).
However, the frequencies of developing metastasis only
confined to distant LN, peritoneum or other organs were
not significantly different between patients with WT and
MT KRAS (Table 6).
Analyses of the clinical predictive factors for liver- or
lung-only metastasis in patients with initial distant
metastasis confined to a single organ (N = 113) were per-
formed including other clinical variables [gender, age (< 65
vs. ≥ 65 years), clinical situations for the development of
systemic metastasis (stage IV at the time of initial CRC
diagnosis vs. recurred after curative resection of stage I - III
CRC), primary tumor sites (colon vs. rectum), histologic
grade, MSI, etc.] along with the KRAS status. Multivariate
logistic regression analysis was carried out using variableswith P-values < 0.10 in univariate analysis. KRAS status
remained predictive for both liver-only and lung-only me-
tastases [odds ratio (OR) = 0.24; 95% confidence interval
(CI), 0.10 – 0.55; P = 0.001 for liver-only metastasis and
OR = 4.20; 95% CI, 1.43 – 12.33; P = 0.009 for lung-only
metastasis, respectively] in the multivariate analysis. Re-
curred cases had increased risk of developing lung-only
metastasis and decreased risk of developing liver-only me-
tastasis compared with initial stage IV cases. Rectal cancer
patients had increased risk of developing lung-only metas-
tasis compared with colon cancer patients; however, the
primary tumor location was not predictive for liver-only
metastasis in the multivariate analysis (Table 7).
Discordance rates of KRAS status according to the
respective metastatic sites
We evaluated the discordance rates of KRAS mutation sta-
tus between primary tumors and paired tissues from vari-
ous metastatic organs (Table 8). The lung was the most
frequent site showing KRAS discordance (32.4%; 12/37);
however, the discordant rate at metastatic sites other than
the lung was 12.3% (13/106) (P = 0.005; Table 8). When
Table 2 Distribution of KRAS mutation types
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tumors and respective metastatic sites (lung, peritoneum,
distant LN or ovary) were compared with the discordance
rate between primary tumors and hepatic metastatic tis-
sues (10.6%), pulmonary metastasis only showed a signifi-
cantly higher discordance rate of KRAS mutation status
(32.4%; P = 0.014). However, no difference in the discord-
ance rate of KRAS status for the other metastatic organs
[peritoneum (13.3%), LN (11.8%), or ovary (18.2%)] was
observed relative to liver metastasis (P-values > 0.05;
Table 8). One patient with tissues acquired from a primary
tumor (colon) and related pancreatic metastatic site showed
concordance of KRAS status (KRAS mutant; Gly12Cys).
Additional analyses were performed to reaffirm whether
the discordance rates of KRAS status were influenced by
other various clinicopathologic factors such as primary
tumor location, type of primary or metastatic tumor speci-
mens (biopsied vs. resected), and the presence of chemo-
therapy (± radiotherapy) before obtaining primary or
metastatic tumor specimens, along with the metastatic
organs. In univariate analyses, rectal cancers showed an
increased KRAS discordance rate when compared with
colon cancers (28.6% vs. 13.9%; P = 0.047), and biopsied
primary tumor specimens showed a trend for an increased
discordant rate when compared with resected primary
tumor specimens (40.0% vs. 15.8%; P = 0.073). However,
the site of metastatic organs (lung vs. liver) only affected
discordant KRAS status in multivariate logistic regression
analysis (OR = 4.03; 95% CI, 1.27 – 12.80; P = 0.018)
(Table 9).
Discussion
To the best of our knowledge, this is the first large-scale
study in which a KRAS mutational analysis was performedTable 3 KRAS mutational status of primary tumors and
paired metastatic sites
KRAS status No. of WT KRAS (P) No. of MT KRAS (P)
No. of WT KRAS (M) 68 12a
No. of MT KRAS (M) 13a 50
a Discordant cases.
Abbreviations: WT, wild-type; P, primary tumors; MT, mutant-type; M, paired
metastatic sites.between primary tumors and corresponding metastases in
Asian MRCRC patients. Overall, a high concordance rate
of KRAS status was observed in Korean MRCRC patients,
as had been previously reported in Western populations.
We observed significant differences in initial metastatic
patterns according to the KRAS mutational status. MT
KRAS tumors developed lung metastases more frequently
as the initial metastatic site; however, liver and distant LN
were more frequently involved as the initial metastatic
sites in WT KRAS tumors. Additionally, the degree of
concordance in KRAS mutational status was significantly
different according to the sites of related metastatic
organs, where the lung was the most frequent metastatic
site showing the discordance of KRAS status.
Our study demonstrated that the clinical presentation of
CRC varied according to the KRAS mutational status.
KRAS mutational status was shown to affect the presenting
pattern of distant metastasis in MRCRC patients. Recurrent
cases after curative treatment for localized diseases were
more common in MT KRAS patients; however, systemic
metastasis was more frequent at the time of initial CRC
diagnosis in WT KRAS patients (Table 1). One previous
study showed that the risk of recurrence was significantly
higher for MT KRAS than WT KRAS tumors in patients
with localized CRC [10]. If localized CRC patients with MT
KRAS had more chances of recurrence, then the MT KRAS
cases would be selected and thus a higher frequency of MT
KRAS in recurrent CRC patients would be expected than
in patients with stage IV disease at the time of initial CRC
diagnosis. However, as our patient cohort is relatively small,
our assumption needs to be further investigated in future
large studies.
In the present study, organs initially involved by distant
metastasis were shown to be different according to the
KRAS mutational status. Patients with MT KRAS had an
initial lung metastasis more frequently than patients with
WT KRAS. In contrast, the WT KRAS patients had liver
or distant LN metastases more frequently as the initial
metastatic sites. However, other metastatic sites such as
the peritoneum were not affected by KRAS status
(Table 5). When the analyses were conducted on patients
with initial distant metastasis confined to a single organ,
the results were similar except for distant LN metastasis
(Table 6). However, since the number of cases with LN-
only metastasis was small (N = 6), the difference of per-
centages (7.7% vs. 3.3%) might not have reached statistical
significance. Although the MT KRAS tumors showed a
trend for more frequent development of peritoneum-only
metastasis (13.5% vs. 27.9%; P = 0.062), it was not statisti-
cally significant (Table 6). In the multivariate analysis,
KRAS status, primary tumor site, and clinical situations
for the development of systemic metastasis were signifi-
cant predictors for liver-only and/or lung-only metastases
(Table 7). The reason why the clinical situations of
Table 4 Analyses of KRAS discordance patterns in KRAS discordant cases (N = 25)
Characteristic WT (P)! MT (M) MT (P)! WT (M) Total N P-value
N (%) N (%)
Clinical situations for the development of systemic metastasis 0.411
Stage IV at the time of initial diagnosis 7 (43.8) 9 (56.3) 16
Recurred after curative resection 6 (66.7) 3 (33.3) 9
Analyzed metastatic sites 0.377
Liver 1 (20.0) 4 (80.0) 5
Lunga 6 (50.0) 6 (50.0) 12
Distant lymph nodes 1 (50.0) 1 (50.0) 2
Peritoneum 3 (75.0) 1 (25.0) 4
Ovary 2 (100.0) 0 (0.0) 2
Abbreviations: WT, wild-type; P, primary tumors; MT, mutant-type; M, paired metastatic sites.
a There was no statistically significant difference in the KRAS discordance pattern between the lung and other paired metastatic organs (P = 1.000).
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involved metastatic organs (liver or lung) is not clear; this
may be related to the process of patient enrollment to this
study as patients with available tissues from both primary
and paired metastatic sites were only included. During this
process, recurred CRC patients with tissue-available lung
metastasis might be selectively included. However, even
after adjusting for these clinical variables, the KRAS muta-
tional status was an independent predictive factor for both
liver-only and lung-only metastases in our study. A previ-
ous study, which analyzed the KRAS status in primary
tumors of CRC patients, showed that there were more
MT KRAS tumors in patients with lung metastasis than in
patients with liver metastasis [14]. Based on this finding,
they suggest that KRAS-mutated primary CRC tumors
can recur with lung metastasis more frequently than withTable 5 Association between initial metastatic or recurred
sites and KRAS mutational status (N = 143)a
Initial metastatic
or recurred site WT KRAS MT KRAS
Total N P-value
N (%) N (%)
Liver < 0.001
Yes 48 (70.6) 28 (37.3) 76
No 20 (29.4) 47 (62.7) 67
Lung 0.003
Yes 15 (22.1) 34 (45.3) 49
No 53 (77.9) 41 (54.7) 94
Distant lymph nodes 0.025
Yes 13 (19.1) 5 (6.7) 18
No 55 (80.9) 70 (93.3) 125
Peritoneum 0.451
Yes 17 (25.0) 23 (30.7) 40
No 51 (75.0) 52 (69.3) 103
Ovaryb 0.885
Yes 5 (7.4) 6 (8.0) 11
No 63 (92.6) 69 (92.0) 132
a Initial metastatic or recurred sites were defined as the organs involved by
distant metastasis at the time point of diagnosis of stage IV cancer (initial
stage IV disease) or recurrence with distant metastasis (recurred cases from
initial stage I-III disease). In these analyses, all enrolled cases (N = 143) were
included.
bAll cases who had Krukenberg tumors as the initial metastatic or recurred
sites had peritoneal metastasis simultaneously. There were no cases with
ovarian metastasis alone without peritoneal metastasis in our study.
Abbreviations: WT, wild-type; MT, mutant-type.liver metastasis. Although the KRAS mutational status
was regarded as positive if KRAS was mutated in any place
of primary tumors or related metastases in the present re-
port, our results also support their suggestion. Further-
more, when the analysis was conducted based on the
KRAS status of primary tumor, the result of our study was
also the same as above. Our work along with previous
studies strongly suggests that the sequence of organs
involved by systemic metastasis is influenced by KRAS
mutational status in CRC patients.
Our results are generally consistent with previous stud-
ies that have reported a high concordance rate of KRAS
mutation (about 90%) between primary and metastatic
tumors [14,15,24-28]. Paired metastatic tissues in previous
studies were mostly derived from the liver [24,26,28] be-
cause these tissues were easily available from hepaticTable 6 Analysis of metastatic patterns among patients
with single organ-only metastasis (N = 113)a
Initial metastatic
or recurred site
WT KRAS MT KRAS Total Na P-value
N (%) N (%)
Liver < 0.001
Yes 34 (65.4) 17 (27.9) 51
No 18 (34.6) 44 (72.1) 62
Lung < 0.001
Yes 6 (11.5) 25 (41.0) 31
No 46 (88.5) 36 (59.0) 82
Distant lymph nodes 0.411
Yes 4 (7.7) 2 (3.3) 6
No 48 (92.3) 59 (96.7) 107
Peritoneumb 0.062
Yes 7 (13.5) 17 (27.9) 24
No 45 (86.5) 44 (72.1) 89
a The association between initial metastatic or recurred sites and KRAS status
was analyzed in patients with metastasis confined to a single organ at the
time of diagnosis of MRCRC (N = 113; 30 patients with initial systemic
metastasis involving ≥ 2 organs simultaneously at the time of diagnosis of
MRCRC were excluded).
b Of 24 patients, cases with simultaneous peritoneal and ovarian metastases
(N = 6) were included; there were no cases with ovarian metastasis alone
without peritoneal metastasis in our study. When patients with peritoneal
metastasis only without Krukenberg tumor (N = 107) were separately
analyzed, the result was not different [WT KRAS 10.0% (5/50) vs. MT KRAS
22.8% (13/57); P = 0.077].
Abbreviations: WT, wild-type; MT, mutant-type; MRCRC, metastatic or recurrent
colorectal cancer.
Table 7 Multivariate logistic regression analysis on the correlation between clinical parameters including KRAS status
and liver- or lung-only metastasesa
Clinical parameter Liver-only metastasis Lung-only metastasis
OR (95% CI) P OR (95% CI) P
KRAS status (MT vs. WT) 0.24 (0.10-0.55) 0.001 4.20 (1.43-12.33) 0.009
Tumor site (rectum vs. colon) - - 3.32 (1.15-9.59) 0.026
Clinical situations for the development of systemic metastasis (recurred vs. stage IV) 0.22 (0.085-0.57) 0.002 6.24 (2.32-16.77) < 0.001
a In this analysis, only variables which had P-values < 0.10 in univariate analysis were included in patients with single organ-only metastasis (N = 113).
Abbreviations: OR, odds ratio; CI, confidence interval; MT, mutant-type; WT, wild-type.
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of KRAS concordance of other metastatic organs other
than the liver have been very limited. Our study evaluated
the KRAS status of metastatic tissues from various organs
besides liver. The degree of KRAS mutational concord-
ance was different according to the related metastatic
sites, with a significantly higher rate of discrepancy in lung
metastases (32.4%) when compared with other metastatic
organs (12.3%) or liver (10.6%) (P-values < 0.05; Table 8).
Although some studies have recently demonstrated a rela-
tively high degree of discordance, with a discordance rate
of up to 50% [11,29-31], there has been no report showing
the site-specific KRAS discordance, as was shown in this
study. The mechanism behind the discordant KRAS muta-
tional status is still not exactly known [31,35,36]. Sampling
errors, heterogeneity within primary tumors, and the de-
velopment of mutations during the process of metastasis
may be the causes of this discordance. The reason why
lung is the most frequent site where the KRAS discordance
takes place is also unknown. In the present study, we ana-
lyzed the pattern of KRAS discordance (i.e. from WT in
primary tumors to MT in related metastatic sites or vice
versa); as the sample size was small (N = 25), the KRAS
discordance pattern did not show any relation to clinical
situations for the development of systemic metastasis
(stage IV vs. recurred) or metastatic organs from which
tumor specimens were obtained. Among 12 cases with
KRAS-discordant lung metastasis, 6 cases (50%) had the
change of KRAS status from WT in a primary tumor to
MT in the lung and 6 cases (50%) had vice versa; there was
no statistically significant difference in the discordance pat-
tern between the lung and other paired metastatic organs
(Table 4). Therefore, the underlying causes of KRASTable 8 The discordant rates of KRAS mutation status betwee




Distant lymph nodes 15 (88.2)
Ovary 9 (81.8)
a The discordant rates of KRAS mutation status between primary tumors and respec
compared with the discordant rate of KRAS status between primary tumor and hep
exact tests.
b The KRAS discordant rate of lung metastasis (32.4%; 12/37) was also significantly
metastatic organs [12.3%; 13/106 (P = 0.005)].discordance need to be further evaluated in future large
studies.
Our study has some limitations. First, this study was per-
formed at a single institution and all MRCRC patients diag-
nosed at our institution were not included. Instead, only
MRCRC patients with both primary and paired metastatic
tissues were consecutively included. In such a process,
unrecognized biases might have influenced our study. Sec-
ond, a KRAS mutational analysis was not repetitively con-
ducted in cases with discordant KRAS status partly because
of insufficient remaining tissue specimens for further exam-
ination. This might raise concerns about the sensitivity of
the KRAS mutation analysis. We actually used traditional se-
quencing (Sanger) method with relatively low sensitivity for
KRAS mutation analysis [37]. In addition, biopsied speci-
mens of primary tumor showed a trend for higher discord-
ance rate than resected specimens in this study (40.0% vs.
15.8%; P = 0.073), although no significance was shown in
multivariate analysis. However, we used tumor cell enrich-
ment by microdissection under the supervision of experi-
enced pathologists to increase the sensitivity of the
sequencing method. In addition, biopsy of primary tumors in
our study was all performed by endoscopy. Actually, a biopsy
of distant metastasis may be more problematic than endo-
scopic biopsy of primary tumors in context of tumor cell
percentage [38]. In the present study, a small number of
metastatic specimens (8/143) was obtained from needle bi-
opsy and only 1 case had KRAS discordance [1/8 (12.5%) for
biopsied metastatic specimens vs. 24/135 (17.8%) for
resected metastatic specimens; P = 1.000]. Moreover, the
concordance rates observed between primary and metastatic
tissues including the liver only (89.4%) or all metastatic
organs other than lung (87.7%) were similar to then primary tumors and respective metastatic sites a,b
Discordant cases, N (%) Total N P-value
5 (10.6) 47 -
12 (32.4) 37 0.014
4 (13.3) 30 0.730
2 (11.8) 17 1.000
2 (18.2) 11 0.607
tive metastatic sites (lung, peritoneum, distant lymph nodes and ovary) were
atic metastatic sites (10.6%) using the Pearson’s chi square or Fisher’s
higher when compared with the discordant rate of combining all other
Table 9 Univariate and multivariate analyses on the association between clinical parameters and the discordance rates
of KRAS mutation statusa
Characteristic Univariate analysis Multivariate analysis
Concordant cases, N (%) Discordant cases, N (%) P OR (95 % CI) P
Metastatic site 0.019
Liver 42 (89.4) 5 (10.6) 1 (Referent)
Lung 25 (67.6) 12 (32.4) 4.03 (1.27-12.80) 0.018
Others 51 (86.4) 8 (13.6) 1.32 (0.40-4.33) 0.649
Tumor site 0.047
Colon 93 (86.1) 15 (13.9) -
Rectum 25 (71.4) 10 (28.6) - -
Type of primary tumor specimens 0.073
Resected 112 (84.2) 21 (15.8) -
Biopsied 6 (60.0) 4 (40.0) - -
a In multivariate analysis, only variables which had P-values < 0.10 in univariate analysis were included.
Abbreviations: OR, odds ratio; CI, confidence interval.
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findings suggest that the high KRAS discordant rate of lung
metastasis (32.4%) had not simply resulted from types of
tumor tissue specimens (biopsied vs. resected) or less sensi-
tive analytic methods performed at our institute. Instead, the
results from our study reflect the real situation of clinical
fields as the traditional sequencing (Sanger) analysis is the
most frequent method used in the real clinical practice set-
ting. More sensitive methods, such as real-time PCR for
KRAS mutation analysis, are only used in the investigational
setting and not widely spread in the clinical practice.
Despite these limitations, our study provides some clinic-
ally meaningful suggestions. The present study demon-
strated that the KRAS mutational status was an
independently predictive factor for organs initially involved
by distant metastasis. This observation implies that surveil-
lance strategies after curative surgery might be tailored to
individual CRC patients according to the KRAS mutational
status. Postoperative surveillance might be more focused
on lung metastasis (i.e., chest computed tomography) in
patients with MT KRAS than in patients with WT KRAS,
when considering the chance of performing metastasect-
omy after the early detection of pulmonary metastasis. Our
study also raised the hypothesis that the discordant rates of
KRAS mutational status might be metastatic site-specific in
CRC. Using the sequencing method, we found different
discordant rates according to the metastatic sites. A
high KRAS discordant rate in patients with lung metastasis,
observed in our study, warrants further large validation
studies.
Conclusions
The concordance rate of KRAS mutation in metastatic
sites was generally high compared with primary tumor
sites in Korean MRCRC patients, as had been previously
reported in Western patients. Organs initially involved by
distant metastasis were different according to the KRAS
mutational status. Individually tailored postoperative sur-
veillance strategies after curative CRC surgery according tothe KRAS mutational status need to be further investigated
in future studies. In addition, lung metastasis had a higher
rate of KRAS discordance (32.4%) than other metastatic
organs, suggesting a possibility of site-specific KRAS dis-
cordance in MRCRC patients. This observation should be
clarified in further large studies.
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